Trucos windows vista regedit5/2/2023 ![]() ![]() Heart transplantation remains an excellent treatment for selected patients with end-stage heart failure and long-term outcome has improved significantly over the past decades.īACKGROUND Tacrolimus, a calcineurin inhibitor, is the cornerstone of immunosuppressive strategies in transplantation. Survival probability by Kaplan–Meier method improved significantly from the mid to the recent era (log-rank p =. Median survival conditional on survival to 1-year follow-up after HTx was 16.1 years. Median survival for the whole cohort was 13.8 years and improved numerically from the early era (12.6 years) to the mid era (14.9 years). Overall, 22% of patients were bridged to HTx with a mechanical circulatory support device. Median number of HTx procedures per year was 12 (10–14). A total of 384 recipients (77% men, median age 50 ) were included. Recipients were grouped by time of transplantation (early era: 1990–1999 mid era: 2000–2009 recent era: 2010–2020). Data were obtained from the Scandinavian Transplant Registry and patient medical records. Consecutive adult patients receiving first-time and isolated HTx from October 3, 1990, to November 2, 2020, at Rigshospitalet, Copenhagen, Denmark, were retrospectively evaluated. The aim of this study was to report on long-term outcome over the past three decades. Heart transplantation (HTx) has become an established treatment option in patients with end-stage heart failure. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |